Minimising immunohistochemical false negative ER classification using a complementary 23 gene expression signature of ER status

PLoS ONE

Volumn 5, Issue 12, 2010, Pages

  Li, Qiyuan ^a   Eklund, Aron C ^a   Juul, Nicolai ^a   Haibe Kains, Benjamin ^b   Workman, Christopher T ^a   Richardson, Andrea L ^c   Szallasi, Zoltan ^a,d   Swanton, Charles ^e,f  

^a TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CELL PROLIFERATION; DISEASE FREE SURVIVAL; ENZYME IMMUNOASSAY; EPITHELIUM CELL; FALSE NEGATIVE RESULT; GENE EXPRESSION; GENE INTERACTION; GENE SEQUENCE; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; KERNEL METHOD; MARKER GENE; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PATIENT CODING; PATIENT SATISFACTION; PROGNOSIS; TREATMENT OUTCOME; BREAST TUMOR; COHORT ANALYSIS; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LABORATORY DIAGNOSIS; METABOLISM; METHODOLOGY; NORMAL DISTRIBUTION;

BREAST NEOPLASMS; COHORT STUDIES; FALSE NEGATIVE REACTIONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NORMAL DISTRIBUTION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTORS, ESTROGEN; TAMOXIFEN; TREATMENT OUTCOME;

EID: 78649923835     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0015031     Document Type: Article

References (38)

1. Barnes DM MR, Beex LV, Thorpe SM, Leake RE (1998) Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. European Journal of Cancer 34.
2. Weigelt B, Mackay A, A'Hern R, Natrajan R, Tan DS, et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol.
3. Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, et al. (2005) Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 97: 1254-1261.
4. Gown AM (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21(Suppl 2): S8-S15.
5. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, et al. (2007) Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a geneexpression profiling study. Lancet Oncol 8: 203-211.
6. Gruvberger S, Ringner M, Chen Y, Panavally S, Saal LH, et al. (2001) Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res 61: 5979-5984.
7. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
8. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
9. Badve S, Nakshatri H (2009) Oestrogen-receptor-positive breast cancer: towards bridging histopathological and molecular classifications. J Clin Pathol 62: 6-12.
10. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, et al. (2008) Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 14: 5158-5165.
11. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, et al. (2008) Metaanalysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10: R65.
12. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN (2007) Standardizing slidebased assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. Clin Cancer Res 13: 2831-2835.
13. Doane AS, Danso M, Lal P, Donaton M, Zhang L, et al. (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25: 3994-4008.
14. Lu X, Wang ZC, Iglehart JD, Zhang X, Richardson AL (2008) Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 108: 191-201.
15. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
16. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Geneexpression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
17. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, et al. (2006) Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24: 4236-4244.
18. Ivshina AV, George J, Senko O, Mow B, Putti TC, et al. (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292-10301.
19. Li Y, Zou L, Li Q, Haibe-Kains B, Tian R, et al. (2010) Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. Nat Med 16: 214-218.
20. Popovici V, Chen W, Gallas BG, Pusztai L, et al. (2009) Effect of training sample size and classification difficulty on the accuracy of genomic predictors. Nature Biotechnol. NA: NA.
21. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, et al. (2008) A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer. Clin Cancer Res 14: 1744-1752.
22. Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, et al. (2009) The 76- gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 116: 303-309.
23. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, et al. (2004) Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 6: 17-32.
24. Li C, Wong WH (2001) Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 98: 31-36.
25. Teschendorff AE, Caldas C (2008) A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer. Breast Cancer Res 10: R73.
26. Bessarabova M, Kirillov E, Shi W, Bugrim A, Nikolsky Y, et al. (2010) Bimodal gene expression patterns in breast cancer. BMC Genomics 11(Suppl 1): S8.
27. Wang J, Wen S, Symmans WF, Pusztai L, Coombes KR (2009) The bimodality index: a criterion for discovering and ranking bimodal signatures from cancer gene expression profiling data. Cancer Inform 7: 199-216.
28. Zilliox MJ, Irizarry RA (2007) A gene expression bar code for microarray data. Nat Methods 4: 911-913.
29. Eklund AC, Friis P, Wernersson R, Szallasi Z (2010) Optimization of the BLASTN substitution matrix for prediction of non-specific DNA microarray hybridization. Nucleic Acids Res 38: e27.
30. Podhajcer OL, Bravo AI, Sorin I, Guman N, Cerdeiro R, et al. (1986) Determination of DNA synthesis, estrogen receptors, and carcinoembryonic antigen in isolated cellular subpopulations of human breast cancer. Cancer 58: 720-729.
31. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC (2009) Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res 11: R7.
32. DeCarlo LT (1997) On the meaning and use of kurtosis. Psychological Methods 2: 292.
33. Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, et al. (1998) Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 52: 227-237.
34. (2001) Tamoxifen for early breast cancer. Cochrane Database Syst Rev: CD000486.
35. Roepman P, Horlings HM, Krijgsman O, Kok M, Bueno-de-Mesquita JM, et al. (2009) Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer. Clin Cancer Res 15: 7003-7011.
36. Allred DC (2008) Commentary: hormone receptor testing in breast cancer: a distress signal from Canada. Oncologist 13: 1134-1136.
37. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, et al. (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25: 3846-3852.
38. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.